Mediolanum International Funds Ltd Has $10.62 Million Position in Axon Enterprise, Inc $AXON

Mediolanum International Funds Ltd raised its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 332.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,967 shares of the biotechnology company’s stock after buying an additional 9,969 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Axon Enterprise were worth $10,615,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hemington Wealth Management grew its holdings in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares in the last quarter. Whipplewood Advisors LLC boosted its position in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 27 shares during the last quarter. NewSquare Capital LLC grew its stake in Axon Enterprise by 96.2% in the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 25 shares in the last quarter. Washington Trust Advisors Inc. grew its stake in Axon Enterprise by 44.7% in the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 17 shares in the last quarter. Finally, TCTC Holdings LLC increased its position in Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 0.5%

NASDAQ:AXON opened at $521.99 on Friday. The company’s 50 day moving average is $681.33 and its 200-day moving average is $731.06. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The firm has a market cap of $41.19 billion, a price-to-earnings ratio of 128.89, a P/E/G ratio of 29.49 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. During the same quarter last year, the business earned $1.45 EPS. The business’s revenue was up 30.6% compared to the same quarter last year. Equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on AXON. Bank of America lifted their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price for the company in a research report on Tuesday, August 5th. Raymond James Financial restated an “outperform” rating and set a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Piper Sandler reduced their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $814.00.

Insiders Place Their Bets

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the transaction, the director directly owned 1,416 shares of the company’s stock, valued at $1,065,596.64. The trade was a 6.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Jennifer H. Mak sold 77 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the transaction, the chief accounting officer owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. The trade was a 0.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 38,622 shares of company stock worth $26,439,364. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.